molecules of the month

BI 730357

Oral RORy nuclear receptor antagonist

on-going Ph. II for psoriasis (QD dosing)

50k cmpd high-conc. frag. screen + scaff. hop

ACS Med. Chem. Lett., Jan. 5, 2021

Boehringer Ingelheim, Ridgefield, CT

Chemical structure of molecule BI-730357
1 min read

The Boehringer RORγ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for plaque psoriasis. We highlighted two other RORγ modulators last year in February and March. While most clinical RORγ modulators have discontinued development after reaching Ph. II, BI 730357’s Ph. II trial appears to be on-going.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: